Expertise in
3
conditions

Dr. Vivek S. Kavadi

Radiation Oncology
Texas Oncology Pharmacy-Sugar Land
1350 First Colony Blvd, 
Sugar Land, TX 
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
Texas Oncology Pharmacy-Sugar Land
1350 First Colony Blvd, 
Sugar Land, TX 

Overview

Vivek Kavadi is a Radiation Oncologist practicing medicine in Sugar Land, Texas.

Dr. Kavadi is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Breast Cancer, Familial Prostate Cancer, and Lung Cancer.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 9 clinical trials. Dr. Kavadi is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Texas Oncology Pharmacy-Sugar Land
1350 First Colony Blvd, Sugar Land, TX 77479

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 8 Less Clinical Trials

23 Total Publications

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.
Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.
Journal: JCO oncology practice
Published: July 07, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Gary B. Gunn
Radiation Oncology
Expertise in
18
conditions
Dr. Gary B. Gunn
Radiation Oncology
Referral may be required

Proton Therapy Center-Houston LTD

1840 Old Spanish Trl, 
Houston, TX 
 (15.6 miles away)
Languages Spoken:
English
See accepted insurances

Gary Gunn is a Radiation Oncologist practicing medicine in Houston, Texas. Dr. Gunn is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Anaplastic Thyroid Cancer, Thyroid Cancer, Adenoid Cystic Carcinoma, Gastrostomy, and Thyroidectomy.

Expertise in
8
conditions
Dr. Ann H. Klopp
Radiation Oncology
Expertise in
8
conditions
Dr. Ann H. Klopp
Radiation Oncology
Referral may be required

Office

1515 Holcombe Blvd Unit 1202, 
Houston, TX 
 (15.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ann Klopp is a Radiation Oncologist practicing medicine in Houston, Texas. Dr. Klopp is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Endometrial Cancer, Vaginal Cancer, and Neuroendocrine Carcinoma of the Cervix. Dr. Klopp is currently accepting new patients.

Expertise in
10
conditions
Dr. Eugene J. Koay
Radiation Oncology
Expertise in
10
conditions
Dr. Eugene J. Koay
Radiation Oncology
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (16.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eugene Koay is a Radiation Oncologist practicing medicine in Houston, Texas. Dr. Koay is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Frequently Asked Questions about Dr. Vivek S. Kavadi

How do I make an appointment with Dr. Vivek S. Kavadi?

You can book an appointment with Dr. Vivek S. Kavadi by calling their office at 281-277-5200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vivek S. Kavadi a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vivek S. Kavadi is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vivek S. Kavadi specialize in?

While Dr. Vivek S. Kavadi is a Radiation Oncology, they have specific expertise in Prostate Cancer, Breast Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Vivek S. Kavadi participate in research or clinical trials?

Yes. Dr. Vivek S. Kavadi has published 23 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Vivek S. Kavadi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vivek S. Kavadi accept my insurance?

Dr. Vivek S. Kavadi accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 281-277-5200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kavadi's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile